ADAPY Adaptimmune Therapeutics plc
Listings ·
A Nasdaq Hearings Panel gave Adaptimmune until December 1, 2025 to meet the $1.00 minimum bid price, or its American Depositary Shares will be delisted. The 8-K gives no share price and no count of days below the floor.
Adaptimmune sold its TECELRA, lete-cel, afami-cel and uza-cel cell therapies to a US WorldMeds subsidiary for $55 million in cash at closing, with up to $30 million more on milestones. The $134 million gain is a pro forma estimate built on March 31, 2025 values.
Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company developing engineered T-cell therapies for solid tumor cancers. Its first product, TECELRA (afamitresgene autoleucel), is approved in the U.S. for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy and whose tumor expresses the MAGE-A4 antigen. The approval is an accelerated approval based on overall response rate and duration of response. The company is planning commercial launch of its second T-cell therapy, letetresgene autoleucel (lete-cel), which targets the NY-ESO antigen and has been studied in synovial sarcoma and myxoid liposarcoma. The FDA granted lete-cel breakthrough therapy designation in January 2025 for myxoid liposarcoma. A collaboration with Galapagos uses uzatresgene autoleucel (uza-cel), made on Galapagos' decentralized manufacturing platform, in a clinical proof-of-concept trial in head and neck cancer. Preclinical programs target PRAME and CD70. In late 2024 the company ceased investment in non-core programs and reduced headcount by approximately 29%, and it is evaluating all strategic options for the company and its programs.
| Product or program | What it is | Stage |
|---|---|---|
| TECELRA (afamitresgene autoleucel) | Engineered T-cell therapy for MAGE-A4-positive synovial sarcoma | approved in the US |
| lete-cel (letetresgene autoleucel) | NY-ESO-targeted T-cell therapy for synovial sarcoma and myxoid liposarcoma | breakthrough therapy designation for myxoid liposarcoma |
| uza-cel (uzatresgene autoleucel) | Engineered T-cell receptor therapy for head and neck cancer, with Galapagos | Phase 1 trial planned |
| ADP-600 | Preclinical T-cell therapy directed to PRAME | preclinical |
| ADP-520 | Preclinical T-cell therapy directed to CD70 | preclinical |
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $178.0 million | $60.3 million |
| Research and development | $149.1 million | $126.5 million |
| Net income (loss) | -$70.8 million | -$113.9 million |
| Cash from operations | -$73.2 million | -$140.9 million |
| Cash and equivalents | $91.1 million | $144.0 million |
| Short-term investments | $60.5 million | $2.9 million |
Our latest story on this, dated Sep 26, 2025: "Adaptimmune gets Nasdaq panel exception until December 1, 2025, to fix bid price". The story links the filing or release it is based on. Read the story.
Adaptimmune Therapeutics plc trades under the ticker ADAPY on OTC.
Adaptimmune Therapeutics plc is listed on OTC.
The SEC Central Index Key (CIK) for Adaptimmune Therapeutics plc is 1621227. Its filings are on SEC EDGAR.
1,590,309,546 shares as of 2025-08-11, per the cover page of its 10-Q filed 2025-08-13.
Our directory records Adaptimmune Therapeutics plc under United Kingdom.
Our directory classifies Adaptimmune Therapeutics plc as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Adaptimmune Therapeutics plc is US00653A1079.
aibio.space lists Adaptimmune Therapeutics plc among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as X0.
Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company developing engineered T-cell therapies for solid tumor cancers. Its first product, TECELRA (afamitresgene autoleucel), is approved in the U.S. for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy and whose tumor expresses the MAGE-A4 antigen.
TECELRA (afamitresgene autoleucel): Engineered T-cell therapy for MAGE-A4-positive synovial sarcoma Stage: approved in the US.
lete-cel (letetresgene autoleucel): NY-ESO-targeted T-cell therapy for synovial sarcoma and myxoid liposarcoma Stage: breakthrough therapy designation for myxoid liposarcoma.
$178.0 million for the fiscal year ended Dec 31, 2024, as reported to the SEC.
Adaptimmune Therapeutics plc reported a net loss of $70.8 million for the fiscal year ended Dec 31, 2024, and used $73.2 million of cash in operations, per its annual report to the SEC.
Filed to end its SEC reporting. SEC Form 15-12G. Source
Filed to remove its shares from exchange listing. SEC Form 25. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.02,2.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,2.05,5.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Reported a leadership departure tied to a disagreement or a restructuring. SEC Form 8-K (Items 5.02,8.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio